The registered randomized study
A 112-patient randomized study, funded by the U.S. Department of Defense and run at Indiana University, compared standard care with standard care plus the electroceutical dressing.
Registry facts
Registry ID: NCT04794621
Sponsor: Indiana University
Collaborators: United States Department of Defense; Naval Medical Research Center
Enrollment: 112 participants (actual)
Dates: Started June 3, 2021; completed July 7, 2023
Design: Randomized, parallel-group; biofilm analysis was performed by outcome assessors blinded to study group (single masking, per the registry).
Comparator: Standard of care alone
Sequential intervention: Standard of care plus PED-10 (Pavaka’s Gen 1 dressing) for three weeks, then a follow-on dressing for three additional weeks
Registry primary outcome: “Response to the use of EDT treatment in prevention of wound biofilm infection” (EDT: electroceutical dressing technology); six-week time frame

Funded by the U.S. Department of Defense
Reported finding
In a 112-patient randomized study funded by the U.S. Department of Defense (NCT04794621), biofilm was measured during the first three weeks, when patients received Pavaka’s Gen 1 dressing. Biofilm abundance fell 40% from the first visit to week 3 in patients on the Gen 1 dressing plus standard care, while the standard-care group did not improve. Full results are being prepared for peer-reviewed publication.
Biofilm results come from the first three weeks of the six-week protocol, when patients used the Gen 1 dressing, and cannot be assumed to apply to later designs. Gen 2 has not been studied in patients.


